These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 1717144)
1. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144 [TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Jain N; Lam YM; Pym J; Campling BG Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
5. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198 [TBL] [Abstract][Full Text] [Related]
6. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143 [TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205 [TBL] [Abstract][Full Text] [Related]
8. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687 [TBL] [Abstract][Full Text] [Related]
9. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148 [TBL] [Abstract][Full Text] [Related]
10. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746 [TBL] [Abstract][Full Text] [Related]
11. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282 [TBL] [Abstract][Full Text] [Related]
12. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932 [TBL] [Abstract][Full Text] [Related]
13. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Wolverton JS; Danks MK; Schmidt CA; Beck WT Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902 [TBL] [Abstract][Full Text] [Related]
14. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377 [TBL] [Abstract][Full Text] [Related]
15. Combined modalities of resistance in etoposide-resistant human KB cell lines. Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393 [TBL] [Abstract][Full Text] [Related]
16. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Takano H; Kohno K; Ono M; Uchida Y; Kuwano M Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696 [TBL] [Abstract][Full Text] [Related]
17. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895 [TBL] [Abstract][Full Text] [Related]
18. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. de Jong S; Zijlstra JG; de Vries EG; Mulder NH Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222 [TBL] [Abstract][Full Text] [Related]
19. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247 [TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Chen M; Beck WT Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]